These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31386648)

  • 41. Pharmacology of adult ADHD with stimulants.
    Spencer TJ
    CNS Spectr; 2007 Apr; 12(4 Suppl 6):8-11. PubMed ID: 17715564
    [No Abstract]   [Full Text] [Related]  

  • 42. Long-acting methylphenidate reduces collision rates of young adult drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Davis M; Mikami AY; Singh H; Merkel RL; Burket R
    J Clin Psychopharmacol; 2012 Apr; 32(2):225-30. PubMed ID: 22367664
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Review of new compounds available in Australia for the treatment of attention-deficit hyperactivity disorder.
    Hazell P
    Australas Psychiatry; 2004 Dec; 12(4):369-75. PubMed ID: 15715810
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Megadose intranasal methylphenidate (ritalin) abuse in adult attention deficit hyperactivity disorder.
    Coetzee M; Kaminer Y; Morales A
    Subst Abus; 2002 Sep; 23(3):165-9. PubMed ID: 12444349
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.
    Weiss M; Hechtman L; Turgay A; Jain U; Quinn D; Ahmed TS; Yates T; Reiz JL; Donnelly GA; Harsanyi Z; Darke AC
    J Child Adolesc Psychopharmacol; 2007 Oct; 17(5):675-88. PubMed ID: 17979587
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy, Safety, and Tolerability of a Novel Methylphenidate Extended-Release Oral Suspension (MEROS) in ADHD.
    Robb AS; Findling RL; Childress AC; Berry SA; Belden HW; Wigal SB
    J Atten Disord; 2017 Dec; 21(14):1180-1191. PubMed ID: 24874348
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
    Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Transdermal methylphenidate system: old wine in a new bottle.
    Bukstein OG
    Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):661-5. PubMed ID: 19442029
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacological management of treatment-induced insomnia in ADHD.
    Kratochvil CJ; Lake M; Pliszka SR; Walkup JT
    J Am Acad Child Adolesc Psychiatry; 2005 May; 44(5):499-501. PubMed ID: 15843773
    [No Abstract]   [Full Text] [Related]  

  • 50. Methylphenidate controlled-delivery capsules (EquasymXL, Metadate CD): a review of its use in the treatment of children and adolescents with attention-deficit hyperactivity disorder.
    Anderson VR; Keating GM
    Paediatr Drugs; 2006; 8(5):319-33. PubMed ID: 17037949
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Successful desensitization of methylphenidate-induced rash.
    Confino-Cohen R; Goldberg A
    J Child Adolesc Psychopharmacol; 2005 Aug; 15(4):703-5. PubMed ID: 16190802
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dexmethylphenidate--Novartis/Celgene. Focalin, D-MPH, D-methylphenidate hydrochloride, D-methylphenidate, dexmethylphenidate, dexmethylphenidate hydrochloride.
    Drugs R D; 2002; 3(4):279-82. PubMed ID: 12455205
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sustained-release methylphenidate: new preparations. New pharmaceutical forms: a slight advantage for a small number of children.
    Prescrire Int; 2004 Dec; 13(74):203-6. PubMed ID: 15612099
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New long-acting stimulants in children with ADHD.
    Rains A; Scahill L
    J Child Adolesc Psychiatr Nurs; 2004; 17(4):177-9. PubMed ID: 15742799
    [No Abstract]   [Full Text] [Related]  

  • 55. Effects of osmotic-release methylphenidate in attention-deficit/hyperactivity disorder as measured by event-related potentials.
    Sawada M; Iida J; Ota T; Negoro H; Tanaka S; Sadamatsu M; Kishimoto T
    Psychiatry Clin Neurosci; 2010 Oct; 64(5):491-8. PubMed ID: 20923428
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dexmethylphenidate for attention deficit hyperactivity disorder.
    Coury D
    Expert Opin Pharmacother; 2009 Nov; 10(16):2679-85. PubMed ID: 19874250
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Medical treatments of hyperactive child: about the new pharmaceutical forms of methylphenidate marketed in France].
    Le Heuzey MF; Vergnaud S; Mouren MC
    Arch Pediatr; 2006 Jan; 13(1):100-3. PubMed ID: 16239100
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A multicenter, open-label trial to evaluate the quality of life in adults with ADHD treated with long-acting methylphenidate (OROS MPH): Concerta Quality of Life (CONQoL) study.
    Mattos P; Louzã MR; Palmini AL; de Oliveira IR; Rocha FL
    J Atten Disord; 2013 Jul; 17(5):444-8. PubMed ID: 22334621
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of two long-acting methylphenidate formulations in children with attention- deficit/hyperactivity disorder in a laboratory classroom setting.
    Silva R; Muniz R; Pestreich LK; Brams M; Childress A; Lopez FA
    J Child Adolesc Psychopharmacol; 2005 Aug; 15(4):637-54. PubMed ID: 16190795
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD.
    McGough JJ; Wigal SB; Abikoff H; Turnbow JM; Posner K; Moon E
    J Atten Disord; 2006 Feb; 9(3):476-85. PubMed ID: 16481664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.